Savara Inc.
This article was originally published in Start Up
Executive Summary
Savara's NanoCluster dry powder aerosol drug delivery platform has potential for local or systemic delivery of a wide variety of drugs. Savara says that since it can precisely tailor its microparticles' sizes, it will improve aerosol efficiency, and thus will be able to deliver two to three times more drug to the lung than competitors' products.
You may also be interested in...
Going To The Angels: Independent Investors Back $16M Series B For Savara
Savara Pharmaceuticals will finance an 80-patient Phase II trial for its inhaled vancomycin candidate as a treatment for MRSA infections in cystic fibrosis patients. Such infections have been linked with a six-year reduction in life expectancy.
Savara Pharmaceuticals
Savara Pharmaceuticals isn’t the first company keen to develop an inhaled version of a well-known antibiotic for treating lung infections in cystic fibrosis patients. But while other companies have developed inhaled forms of antibiotics against the relatively common infectious organism Pseudomonas aeruginosa, Savara is targeting an equally dangerous bug, methicillin-resistant Staphylococcus aureus.
Start-Up Previews (07/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Eye Macular Degeneration," features profiles of Acucela, Iconic Therapeutics, MacuCLEAR, Ophthotech, Optherion and Sirion Therapeutics. "Scoping Out Gastroenterology Start-Ups" features profiles of invendo medical, Mauna Kea Technologies and Softscope Medical Technologies. Plus these Start-Ups Across Health Care: Bone Solutions, Cardioxyl Pharmaceuticals, Savara and VasoNova.